Creative Planning Has $206,000 Stake in Annexon, Inc. (NASDAQ:ANNX)

Creative Planning boosted its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 29.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,779 shares of the company’s stock after acquiring an additional 7,914 shares during the period. Creative Planning’s holdings in Annexon were worth $206,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ANNX. Ameritas Investment Partners Inc. lifted its position in Annexon by 78.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock worth $48,000 after acquiring an additional 2,949 shares during the last quarter. Sandia Investment Management LP acquired a new position in shares of Annexon during the second quarter valued at about $49,000. Victory Capital Management Inc. acquired a new position in shares of Annexon during the second quarter valued at about $51,000. Principal Financial Group Inc. acquired a new position in shares of Annexon during the second quarter valued at about $56,000. Finally, Comerica Bank acquired a new position in shares of Annexon during the first quarter valued at about $72,000.

Insiders Place Their Bets

In other Annexon news, EVP Ted Yednock sold 4,500 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $7.10, for a total transaction of $31,950.00. Following the sale, the executive vice president now directly owns 71,365 shares of the company’s stock, valued at approximately $506,691.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 20,908 shares of company stock valued at $135,768. 12.67% of the stock is currently owned by insiders.

Annexon Stock Down 3.6 %

NASDAQ:ANNX opened at $6.97 on Tuesday. Annexon, Inc. has a 12-month low of $2.10 and a 12-month high of $8.40. The firm has a market capitalization of $736.38 million, a PE ratio of -5.67 and a beta of 1.23. The firm has a 50-day moving average price of $6.82 and a 200 day moving average price of $5.87.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). On average, research analysts expect that Annexon, Inc. will post -0.97 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research report on Monday, September 9th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Annexon has a consensus rating of “Buy” and an average price target of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.